Rama Suresh

6PUBLICATIONS
83CO-AUTHORS
Tumour immunologyCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Feb 06, 2026
Neoadjuvant Endocrine Treatment plus Mammaglobin-A DNA Vaccine Induces Antitumor Immune Responses in the Primary Tumor and Peripheral Blood of Patients with Breast Cancer: Insights from a Phase Ib Clinical Trial.

Rashmi Mishra, Foluso Ademuyiwa, Yilin Yang

|Mar 24, 2025
Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer.

Patrick M Grierson, Crystal Wolf, Rama Suresh

|Mar 21, 2025
Detection of Circulating Tumor DNA Using a Tissue-Free Epigenomic Assay Is a Highly Prognostic Biomarker in Early-Stage Triple-Negative Breast Cancer.

Foluso O Ademuyiwa, Cynthia X Ma, Katherine Weilbaecher

|Oct 06, 2023
A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy.

Patrick M Grierson, Rama Suresh, Benjamin Tan

|Jan 24, 2023
Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor-Positive (HR+)/HER2-Negative Metastatic Breast Cancer.

Andrew A Davis, Jingqin Luo, Tiantian Zheng

|Oct 13, 2022
Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study.

Andrea Wang-Gillam, Kian-Huat Lim, Robert McWilliams

Pageof 1

Frequent Collaborators

3 joint publications

Andrea Wang-Gillam

3 joint publications

Kian-Huat Lim

3 joint publications

Foluso O Ademuyiwa

3 joint publications

Amberly Brown